A detailed history of Fred Alger Management, LLC transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Fred Alger Management, LLC holds 1,243,717 shares of PCVX stock, worth $110 Million. This represents 0.72% of its overall portfolio holdings.

Number of Shares
1,243,717
Previous 1,310,436 5.09%
Holding current value
$110 Million
Previous $99 Million 43.5%
% of portfolio
0.72%
Previous 0.49%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$70.52 - $117.12 $4.71 Million - $7.81 Million
-66,719 Reduced 5.09%
1,243,717 $142 Million
Q2 2024

Aug 14, 2024

SELL
$60.06 - $78.77 $5.18 Million - $6.8 Million
-86,275 Reduced 6.18%
1,310,436 $99 Million
Q1 2024

May 15, 2024

SELL
$59.79 - $81.05 $16.4 Million - $22.2 Million
-273,478 Reduced 16.37%
1,396,711 $95.4 Million
Q4 2023

Feb 14, 2024

SELL
$45.35 - $63.41 $19.2 Million - $26.8 Million
-423,116 Reduced 20.21%
1,670,189 $105 Million
Q3 2023

Nov 14, 2023

SELL
$46.0 - $53.1 $12.8 Million - $14.8 Million
-277,913 Reduced 11.72%
2,093,305 $107 Million
Q2 2023

Aug 14, 2023

BUY
$34.66 - $54.07 $52.9 Million - $82.5 Million
1,526,440 Added 180.69%
2,371,218 $118 Million
Q1 2023

May 15, 2023

SELL
$36.27 - $47.2 $1.18 Million - $1.53 Million
-32,515 Reduced 3.71%
844,778 $31.7 Million
Q4 2022

Feb 14, 2023

BUY
$20.58 - $47.95 $18.1 Million - $42.1 Million
877,293 New
877,293 $42.1 Million
Q2 2022

Aug 15, 2022

SELL
$17.68 - $26.58 $171,089 - $257,214
-9,677 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$17.46 - $26.36 $168,960 - $255,085
9,677 New
9,677 $234,000

Others Institutions Holding PCVX

About Vaxcyte, Inc.


  • Ticker PCVX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,315,100
  • Market Cap $5.25B
  • Description
  • Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...
More about PCVX
Track This Portfolio

Track Fred Alger Management, LLC Portfolio

Follow Fred Alger Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fred Alger Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fred Alger Management, LLC with notifications on news.